Life sciences specialist Merchant Opportunities Fund ups stake in Rhythm
After going substantial on 12 June, Merchant Group has increased its equity stake in RHY.ax from 5.02% to 7.01%, purchasing an additional 2,000,000 for $449,561, equating to $0.225 per share.
Biotech investor Merchant Group becomes a substantial holder of RHY
Rhythm Biosciences welcomes leading biotechnology investor Merchant Group as a substantial holder, buying at between $0.18 and 0.21, average 0.1915 (Refer Annexure A). The Merchant Opportunities Fund, which now holds 5,060,000 FPO or 5.02 percent of Rhythm (up from 2,200,000 units as reported on Sprout8 Twitter…
RHY: An attractive medical diagnostics technology company
RHYTHM BIOSCIENCES LIMITED ASX:RHY Excellent prognosis: An attractive medical diagnostics technology company Authored by N.A.S. at Sprout8.com Date: 13/5/2018 Current Price: $0.18 If you only have 5 minutes, we recommend you read: Investment View; Critical Path to Commercialisation, including our perceived risk levels; and Valuation….
- Infographic: Excellent prognosis: Developments in Colorectal Cancer Testing – What is Likely to Become The Preferred Test For Population Screening (Part 2 of 2)
- Update: Netflix the Sore Tooth in FANG?
- Infographic: Excellent prognosis: A Primer on Cancer Screening – How Early Detection Can Save Lives and Produce Excellent Investment Returns (Part 1 of 2)
- Netflix the Sore Tooth in FANG?
- Life sciences specialist Merchant Opportunities Fund ups stake in Rhythm